Geode Capital Management LLC Purchases 29,686 Shares of Guardant Health, Inc. (NASDAQ:GH)

Geode Capital Management LLC boosted its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 1.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,822,220 shares of the company's stock after buying an additional 29,686 shares during the quarter. Geode Capital Management LLC owned 2.28% of Guardant Health worth $64,754,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cerity Partners LLC grew its holdings in Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company's stock worth $4,473,000 after acquiring an additional 68,883 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Guardant Health by 1,282.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock valued at $28,128,000 after buying an additional 1,137,482 shares in the last quarter. First Light Asset Management LLC grew its position in shares of Guardant Health by 119.7% in the 2nd quarter. First Light Asset Management LLC now owns 416,967 shares of the company's stock worth $12,042,000 after acquiring an additional 227,202 shares in the last quarter. Pier Capital LLC increased its holdings in shares of Guardant Health by 36.7% in the 3rd quarter. Pier Capital LLC now owns 158,429 shares of the company's stock valued at $3,634,000 after acquiring an additional 42,575 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in Guardant Health by 52.7% in the third quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company's stock worth $27,007,000 after purchasing an additional 406,500 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Price Performance

Shares of Guardant Health stock traded up $0.54 during trading on Friday, hitting $31.67. The stock had a trading volume of 2,414,304 shares, compared to its average volume of 2,035,487. The business has a fifty day moving average of $29.13 and a two-hundred day moving average of $28.35. The firm has a market cap of $3.91 billion, a P/E ratio of -7.47 and a beta of 1.26. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $38.53. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. During the same period in the previous year, the company posted ($0.73) earnings per share. Guardant Health's revenue was up 33.9% compared to the same quarter last year. On average, sell-side analysts expect that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the business's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now owns 7,648 shares in the company, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Musa Tariq sold 2,320 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company's stock, valued at $93,660. This represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,432 shares of company stock valued at $175,423. Corporate insiders own 5.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Sanford C. Bernstein decreased their target price on Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday, October 30th. The Goldman Sachs Group raised their price target on Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, Leerink Partners cut their target price on Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. Fifteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $40.60.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.